Recall Record: Class II Recall: RayCare 2024A SP1. Oncology Information Systems. by RAYSEARCH LABORATORIES AB

Key facts

What consumers should do

Facilities, clinicians, and consumers holding an affected unit or lot of RayCare 2024A SP1. Oncology Information Systems. should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from RAYSEARCH LABORATORIES AB. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from RAYSEARCH LABORATORIES AB should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to RAYSEARCH LABORATORIES AB directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.

What this classification means

A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.

RAYSEARCH LABORATORIES AB’s FDA history

Argus HQ has recorded 2 total FDA actions tied to RAYSEARCH LABORATORIES AB: 0 warning letters, 2 recalls, 0 approval records, and 0 Form 483 inspection citations.

Frequently asked questions

Why was RayCare 2024A SP1. Oncology Information Systems. recalled?

FDA's recall record states the reason as: Beam set delivery note issues in which there is potential data loss if the beam set delivery note is modified simultaneously and/or if a note is updated during a treatment session, the user is not notified of the change.

Who should I contact about this recall?

Contact RAYSEARCH LABORATORIES AB directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.

Has RAYSEARCH LABORATORIES AB had other FDA recalls or enforcement actions?

Yes. Argus HQ has recorded 2 total FDA actions tied to RAYSEARCH LABORATORIES AB, including 2 recalls and 0 warning letters.

What is the FDA recall number for this event?

FDA recall number Z-2646-2026.

Related enforcement actions

• Recall: RAYSEARCH LABORATORIES AB — Class II recall: RayCare 2024A SP4. Oncology Information Systems. →